EFM
SAGE

E Fund Management’s Sage Therapeutics SAGE Stock Holding History

E Fund Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,544
Closed -$348K – 369
2024
Q1 		$348K Buy
18,544
+2,062
+13% +$47.6K 0.02% 254
2023
Q4 		$357K Sell
16,482
-4,678
-22% -$92.7K 0.02% 209
2023
Q3 		$435K Buy
21,160
+13,703
+184% +$396K 0.03% 147
2023
Q2 		$351K Sell
7,457
-1,955
-21% -$97.3K 0.03% 198
2023
Q1 		$395K Buy
9,412
+824
+10% +$35.4K 0.03% 170
2022
Q4 		$328K Sell
8,588
-2,753
-24% -$105K 0.03% 215
2022
Q3 		$444K Buy
11,341
+446
+4% +$17.2K 0.04% 153
2022
Q2 		$352K Buy
10,895
+2,261
+26% +$75.8K 0.03% 208
2022
Q1 		$286K Buy
+8,634
New +$325K 0.01% 211

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

E Fund Management's SAGE Position: Q2 2024 in Review

E Fund Management sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 18,544 shares — an estimated $348K sold.

E Fund Management first reported a position in SAGE in Q1 2022 and held it in 9 quarters. The position peaked at $444K in Q3 2022. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • E Fund Management reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • E Fund Management sold 18,544 Sage Therapeutics shares in Q2 2024, an estimated $348K.
  • E Fund Management first reported a position in Sage Therapeutics in Q1 2022 and held it in 9 quarters.
  • E Fund Management's Sage Therapeutics position peaked at $444K in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.